AI in drug repurposing for cancer therapies
Abstract
Artificial intelligence (AI) is transforming drug discovery by enabling the rapid identification of existing drugs with potential anti-cancer properties, a process known as drug repurposing. This approach offers a cost-effective and time-efficient alternative to traditional drug development, particularly in oncology, where the need for novel therapies is urgent. AI-driven methods, including machine learning (ML) and deep learning (DL), analyze vast datasets to uncover hidden drug-disease relationships, predict drug efficacy, and optimize therapeutic combinations. This letter highlights the transformative potential of AI in drug repurposing for cancer therapies, supported by successful examples from recent research. We also discuss the challenges and ethical considerations of integrating AI into drug repurposing efforts, emphasizing the need for robust validation and regulatory oversight to ensure patient safety and efficacy.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.